Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Bevacizumab in Relapsed Astrocytoma
NCT05518994Phase 2Not yet recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in astrocytoma (3 arms), sponsored by Henan Provincial People's Hospital. Primary endpoint: Overall Survival Rate at 24 months. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
astrocytoma
Beyond the preview
Go deeper on NCT05518994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518994.